A Phase IIIB, multi-centre open label, follow-up study to evaluate the safety and efficacy of certolizumab pegol administered concomitantly with DMARDs in subjects with active rheumatoid arthritis who participated in the study C87076 [Extension of profile 34136].

Trial Profile

A Phase IIIB, multi-centre open label, follow-up study to evaluate the safety and efficacy of certolizumab pegol administered concomitantly with DMARDs in subjects with active rheumatoid arthritis who participated in the study C87076 [Extension of profile 34136].

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2014

At a glance

  • Drugs Certolizumab pegol (Primary) ; Disease-modifying antirheumatics
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms CERTAIN-2
  • Sponsors UCB
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Feb 2013 New trial record
    • 17 Dec 2012 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top